PRTC vs. ONT, GNS, ERGO, SLN, OXB, HZD, VRP, FARN, ARIX, and BVXP
Should you be buying PureTech Health stock or one of its competitors? The main competitors of PureTech Health include Oxford Nanopore Technologies (ONT), Genus (GNS), Ergomed (ERGO), Silence Therapeutics (SLN), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), Faron Pharmaceuticals Oy (FARN), Arix Bioscience (ARIX), and Bioventix (BVXP). These companies are all part of the "biotechnology" industry.
PureTech Health vs.
PureTech Health (LON:PRTC) and Oxford Nanopore Technologies (LON:ONT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, community ranking, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.
In the previous week, PureTech Health had 2 more articles in the media than Oxford Nanopore Technologies. MarketBeat recorded 2 mentions for PureTech Health and 0 mentions for Oxford Nanopore Technologies. PureTech Health's average media sentiment score of 0.34 beat Oxford Nanopore Technologies' score of 0.00 indicating that PureTech Health is being referred to more favorably in the media.
Oxford Nanopore Technologies has a net margin of -94.82% compared to PureTech Health's net margin of -17,620.94%. PureTech Health's return on equity of -21.15% beat Oxford Nanopore Technologies' return on equity.
PureTech Health received 497 more outperform votes than Oxford Nanopore Technologies when rated by MarketBeat users. However, 100.00% of users gave Oxford Nanopore Technologies an outperform vote while only 86.60% of users gave PureTech Health an outperform vote.
PureTech Health has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Oxford Nanopore Technologies has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.
PureTech Health presently has a consensus target price of GBX 455, indicating a potential upside of 220.42%. Oxford Nanopore Technologies has a consensus target price of GBX 235.50, indicating a potential upside of 101.63%. Given PureTech Health's higher possible upside, research analysts plainly believe PureTech Health is more favorable than Oxford Nanopore Technologies.
79.9% of PureTech Health shares are held by institutional investors. Comparatively, 38.4% of Oxford Nanopore Technologies shares are held by institutional investors. 15.9% of PureTech Health shares are held by insiders. Comparatively, 32.6% of Oxford Nanopore Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
PureTech Health has higher earnings, but lower revenue than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.
Summary
PureTech Health beats Oxford Nanopore Technologies on 11 of the 17 factors compared between the two stocks.
Get PureTech Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
PureTech Health Competitors List
Related Companies and Tools
This page (LON:PRTC) was last updated on 2/22/2025 by MarketBeat.com Staff